Furthermore, FGFR inhibitors have been shown to increase the infiltration of anti-tumour immune cells, such as CD8+ T cells and M1 TAMs, while inhibiting the infiltration of pro-tumour immune cells, such as MDSCs and M2 TAMs. Here, CD8A is linked to neoplasm.